HCAT vs MRT

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for HCAT turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

HCAT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HCAT crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for HCAT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HCAT's RSI Indicator exited the oversold zone, 30 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for HCAT moved above the 200-day moving average on October 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

HCAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.090) is normal, around the industry mean (4.477). P/E Ratio (-0.397) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.429) is also within normal values, averaging (6.065).

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. HCAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HCAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 60 cases where MRT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRT as a result. In 56 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.

MRT broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for MRT just turned positive on October 21, 2026. Looking at past instances where MRT's MACD turned positive, the stock continued to rise in 32 of 53 cases over the following month. The odds of a continued upward trend are 60%.

MRT moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MRT crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.

Following a +11.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRT advanced for three days, in 97 of 143 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

The Aroon Indicator entered an Uptrend today. In 75 of 212 cases where MRT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 35%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.139) is normal, around the industry mean (-1.906). P/E Ratio (-4.140) is within average values for comparable stocks, (9.554). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.824). Dividend Yield (0.038) settles around the average of (0.069) among similar stocks. P/S Ratio (2.829) is also within normal values, averaging (70.383).

The Tickeron Seasonality Score of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. MRT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.